96 results
8-K
EX-99.1
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
27 Dec 23
Completion of Acquisition or Disposition of Assets
8:25pm
(NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842). Additional indications for the active ingredient
425
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
18 Dec 23
Business combination disclosure
6:02am
referred to below, conducting presentations, and granting access to virtual data rooms. None of these discussions had yet matured to term sheets
8-K
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
18 Dec 23
Other Events
6:01am
referred to below, conducting presentations, and granting access to virtual data rooms. None of these discussions had yet matured to term sheets
424B3
CYTH
Cyclo Therapeutics Inc - Ordinary Shares
21 Nov 23
Prospectus supplement
9:15am
required information, you will receive further instruction via email, that provides you access to the AMTI special meeting, and allows you to vote … in the treatment of Alzheimer’s disease. In January 2018, the FDA authorized a single patient IND expanded access program using Trappsol® Cyclo™ for the treatment
S-4/A
s7q7t1fqfz4acr
20 Nov 23
Registration of securities issued in business combination transactions (amended)
8:50am
S-4
6w7ur6 4y2u
7 Nov 23
Registration of securities issued in business combination transactions
4:45pm
425
EX-99.1
odwlv7w39wj407h0zi
21 Sep 23
Business combination disclosure
4:28pm
425
EX-2.1
j4h0k6sq7wd5ywsqdl2d
21 Sep 23
Business combination disclosure
4:28pm
8-K
EX-2.1
rzyqyckvurywu4j9lcte
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
4:28pm
8-K
EX-99.1
acjcxqt
21 Sep 23
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
4:28pm
8-K
EX-10.2
y7ntin29m8ejs45q
4 May 23
Unregistered Sales of Equity Securities
3:42pm